Comparative Pharmacology
Head-to-head clinical analysis: CHROMITOPE SODIUM versus TECHNESCAN HIDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMITOPE SODIUM versus TECHNESCAN HIDA.
CHROMITOPE SODIUM vs TECHNESCAN HIDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
None Documented
None Documented
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours.
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical